Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other
AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients...
Fraud Surges in APAC's Fastest-Growing Industries--Sumsub Report Highlights a 723% Spike in Healthtech, 116% in Fintech
Fraudsters increasingly weaponize AI-powered deepfakes and synthetic identity documents to exploit the expanding digital ecosystems in APAC Deepfake scams remain a persistent threat, Singapore sees a 1,500% surge; Hong Kong SAR jumps 1,900%...
Hisense TV Retains Global No.2 Ranking in 2024 and Leads the 100-Inch TV Market Worldwide
QINGDAO, China, Feb. 18, 2025 /PRNewswire/ -- Hisense, a leading global home appliance and consumer electronics brand, has reinforced its competitive strength in the global market. Hisense's global TV shipments reached 29.14 million units in 2024,...
Hisense TV Shipment Share at 14.06% in 2024, Maintains Top Two Global Position for Three Consecutive Years
QINGDAO, China, Jan. 26, 2025 /PRNewswire/ -- Hisense, a leading brand in global consumer electronics and home appliances, has reinforced its dominance in the global TV market achieving an unprecedented three consecutive years of second-highest...
Hisense Transforms the Future of Home Entertainment and Smart Living with AI-powered Innovation at CES 2025
QINGDAO, China, Jan. 8, 2025 /PRNewswire/ -- Hisense, a leading brand in global consumer electronics and home appliances, unveiled the latest in AI-based technological innovation at its "AI Your Life" themed booth at CES 2025, captivating audiences...